Form 4: Integrated BioPharma Director Damon DeSantis Acquires Stock Options
SEC Form 4 Filing
Director Damon DeSantis reports acquisition of stock options in Integrated BioPharma Inc.
Summary
- On August 7, 2024, Damon DeSantis, a director of Integrated BioPharma Inc. (INBP), acquired 50,000 stock options.
- The options have an exercise price of $0.18.
- The stock options vest in four equal installments starting September 30, 2024, and ending June 30, 2025.
- The expiration date for these options is August 7, 2034.
- Following the transaction, DeSantis directly owns 50,000 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of stock options by a director could be interpreted as a positive signal, but it's a routine disclosure.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/07/2024 | Date of transaction: Damon DeSantis acquired stock options. |
| 08/07/2024 | Date of transaction: Damon DeSantis acquired stock options. |
| 09/30/2024 | First vesting date for 12,500 stock options. |
| 12/31/2024 | Second vesting date for 12,500 stock options. |
| 03/31/2025 | Third vesting date for 12,500 stock options. |
| 06/30/2025 | Fourth vesting date for 12,500 stock options. |
| 08/07/2034 | Expiration date of the stock options. |
Keywords
stock options, Form 4, INBP, Integrated BioPharma, Damon DeSantis, director, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.